Researchers from Lawrence Livermore National Laboratory (LLNL), in collaboration with other leading institutions, have ...

New research links multisystem inflammatory syndrome in children with COVID-19 to Epstein-Barr virus reactivation, revealing ...

Background Infectious agents such as SARS-CoV-2 require strategies to contain outbreaks, particularly in hospitals where the ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

COVID-19 has continued to alarm public health, and although several therapeutics and vaccines have been developed, the development of effective vaccines or antibodies is challenging due to mutations ...

Researchers at Umeå University have discovered that the SARS-CoV-2 variant omicron has developed a stronger binding to human ...

As we reflect on five years since the tumultuous start of the COVID pandemic (even if we just wish to forget it ever happened ...

There are no clear criteria to mark the end of a pandemic, and the virus that causes the disease — SARS-CoV-2 — continues evolving and infecting people worldwide. “Whether the pandemic ended ...

In this study, the adhesion-blocking dispirotripiperazine core compound PDSTP was evaluated against SARS-CoV-2 in vitro and in vivo. We demonstrated that the molecule was acceptably active against two ...